Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas

Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas

Abstract Background Programmed cell death ligand-1 (PD-L1) expression has been reported in up to 61% of high grade gliomas (HGG). The purpose of this study was to describe safety and efficacy of PD-1 inhibition in patients with refractory HGGs. Methods This Institutional Review Board approved single...

Full description

Bibliographic Details
Main Authors: Samantha N. Reiss, Prakirthi Yerram, Lisa Modelevsky, Christian Grommes
Format: Article
Language:English
Published: BMJ Publishing Group 2017-12-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Glioblastoma
Immune checkpoint
High-grade glioma
PD-1
PD-L1
Pembrolizumab
Online Access:http://link.springer.com/article/10.1186/s40425-017-0302-x

Internet

http://link.springer.com/article/10.1186/s40425-017-0302-x

Similar Items